RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.jimsenior - interesting read given that the CD47 has limited effectiveness and would need to be combined with an immune checkpoint inhibitor AND ONCY's pelareorep in order for the combination to postiviely affect the immune system. I think that Pfizer is aware of their limitations with CD47 and are developing sasanslimab, a SC administered PD-(L)1 checkpoint inhibitor to facilitate their Trillium Therapeutics acquisition. So I think that Pfizer wants ONCY's pelareorep as an "immunostimulant", given that Pfizer's CEO Albert Bourla has already signaled in that direction.
https://timmermanreport.com/2023/03/jan-skvarka-former-trillium-ceo-on-driving-a-turnaround/